MASH

A GLOBAL EPIDEMIC

MAFLD (Metabolic Associated Fatty Liver Disease – formerly NAFLD) has rapidly become the most common chronic liver disease linked to metabolic health diseases such as obesity and type 2 diabetes with a prevalence greater than 1/3 of the worldwide population. MASH (Metabolic Associated SteatoHepatitis – formerly NASH) is the most severe form of the disease that can lead to irreversible and life threatening cirrhosis or cancer.

MALFD is also known as « Fatty liver disease » or « Soda disease » because it’s directly influenced by modern lifestyles (processed food, high-fat diets, sedentary habits, …).

MAFLD is characterized by a fatty liver (Steatosis) and its rapid increase by obesity, an epidemic that evolves in parallel.

MASH is characterized by the presence of inflammation and liver fibrosis (main determinant of the disease severity) in addition to a fatty liver.

The healthcare associated economic burden is enormous. The latest evaluation estimates the related annual cost of $103 billion in the United States and $52 billion in Europe linked to MAFLD/MASH.

MAFLD and MASH IN FIGURES

90%

OBESE ADULTS WITH DIABETES TYPE II HAVE HEPATHIC STEATOSIS

1 in 3

ADULT WORLDWIDE SUFFERS LIVER STEATOSIS

1st

LEADING CAUSE OF CHRONIC LIVER DISEASE

1 in 20

ADULT GLOBALLY ESTIMATED
TO LIVE WITH MASH

Up to 40x

HIGHER RISK OF LIVER COMPLICATIONS IN ADVANCED FIBROSIS OR CIRRHOSIS PATIENTS

1st

LEADING CAUSE OF HEPATIC TRANSPLANTATION

1 in 4

LIVER CANCER IS A MAFLD CASE

80%

MASH PATIENTS NOT DIAGNOSED IN THE UK

+63%

INCREASE IN MASH PATIENTS IN THE USA BETWEEN 2015 AND 2030

+13K€

YEARLY COST PER PATIENT AFFECTED BY MASH IN EUROPE

Designed for University Hospitals, Centers specialized in liver diseases, Pharmaceutical companies and CROs

MORE INFO
ELiBio Software

THE CHALLENGE OF DIAGNOSIS

MASH generally develops without symptoms.

That is why MASH is usually diagnosed at a late stage.

The current gold standard diagnostic method is liver biopsy. However, biopsy is an invasive, painful and costly procedure and it presents risks of complications.

Other non-invasive methods exist and are performant to identify patients at risk of cirrhosis/cancer and patients without risk of MASH. Such methods however fail to identify patients in between, especially patients at early-stage of MASH, whose diagnosis remains a challenge for clinicians.

As the disease naturally progresses, the liver health deteriorates towards cirrhosis and liver cancer. Early-stage diagnosis is therefor key to provide optimal care while the liver damage can be reversed and avoid such dramatic – irreversible and often deadly – complications.

SoQut-Imaging provides a reliable non-invasive diagnostic methods to identify MASH early , answering this urging clinical need globally.

I'll book an appointment!

Need a demo?
Get in touch with us!